Genentech : Ocrevus Data Reinforce Benefit On Slowing Disease Progression In Multiple Sclerosis

Genentech, a member of the Roche Group (RHHBY), said new analyses showed that early treatment with Ocrevus or ocrelizumab may significantly control disease progression in both relapsing-remitting multiple sclerosis and in primary progressive multiple sclerosis. Controlling progression can enable people with multiple sclerosis to maintain mobility and limit their disability.

In addition, data show that more people with multiple sclerosis are staying on Ocrevus, the only twice-yearly treatment for multiple sclerosis, compared with other therapies, which may translate to improved outcomes, the company said in a statement.

Ocrevus treatment provided consistent benefit over one year in patients who were recently diagnosed with relapsing-remitting multiple sclerosis or RRMS and had not received prior disease modifying treatment (DMT) in an interim analysis of open-label Phase IIIb study ENSEMBLE.

After 48 weeks, 85% of Ocrevus-treated early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity.

Ocrevus treatment significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis in post-hoc analysis of Phase III ORATORIO study.

Ocrevus-treated patients showed highest adherence and persistence rates compared with other disease-modifying therapies in two-year U.S. claims analysis.

Ocrevus is approved in 95 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland, the United Kingdom and the EU.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT